Slc22a1-flox Mouse

Slc22a1, also known as the gene encoding the broad selectivity transporter hOCT1, is expressed in most epithelial barriers and different drug target cells [2]. It contributes to drug pharmacokinetics and pharmacodynamics, mediating the translocation of various drugs, such as metformin, anticancer, antiviral, anti-inflammatory agents [2].

In chronic myeloid leukemia (CML), carriers of SLC22A1 rs628031A allele or rs683369G allele are associated with a lower major molecular response (MMR) rate to imatinib treatment [1]. In Mexican women, genetic variants in SLC22A1 are related to serum lipid levels, with certain genotypes and haplotypes associated with changes in cholesterol and lipoprotein levels [3]. In children with acute lymphoblastic leukemia in the Amazon region, the SLC22A1 gene variant is associated with a higher risk of severe infectious toxicity during treatment [4].

In conclusion, Slc22a1 plays a crucial role in drug disposition and therapeutic responses. Its genetic variants are associated with different disease-related outcomes, including drug response in CML, lipid metabolism in Mexican women, and treatment-related toxicity in childhood leukemia. Understanding Slc22a1 through genetic models helps uncover its role in these biological processes and disease conditions.